Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 2:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Adjunct Therapy Clear all
Recruiting Not applicable Interventional

Cortical Stimulation to Treat Obsessive Compulsive Disorder

NCT04958096
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Standard Therapeutic Deep Brain Stimulation, Cortical Stimulation for PFC, Cortical Stimulation for ACC
Device
Lead sponsor
Andrew Moses Lee, MD, PhD
Other
Eligibility
22 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 21, 2026, 2:33 PM EDT
Completed Not applicable Interventional

Effects of Osteopathic Manipulative Therapy on Arrhythmias

NCT04004741
View directory record Official record
Conditions
Cardiac Arrhythmia
Interventions
Osteopathic Manipulative Treatment, Light Touch Therapy
Procedure
Lead sponsor
New York Institute of Technology
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Glen Head, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Sep 21, 2026, 2:33 PM EDT
Recruiting Not applicable Interventional

Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors

NCT03463954
View directory record Official record
Conditions
Malignant Neoplasm of Breast
Interventions
Novilase Laser ablation
Device
Lead sponsor
Novian Health Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Duarte, California • La Jolla, California • Rancho Mirage, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 21, 2026, 2:33 PM EDT
Completed Not applicable Interventional

Feasibility and Tolerability of Adjunct Chronotherapy in Depressed Inpatients

NCT02088580
View directory record Official record
Conditions
Non-Psychotic Unipolar Depression, Bipolar Depression
Interventions
Triple Chronotherapy
Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Sep 21, 2026, 2:33 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Head and Neck Cancer

NCT00404339
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
mutant p53 peptide pulsed dendritic cell vaccine, tetanus toxoid helper peptide, adjuvant therapy
Biological · Procedure
Lead sponsor
Robert Ferris
Other
Eligibility
18 Years to 120 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2016 · Synced Sep 21, 2026, 2:33 PM EDT
Completed Phase 1 Interventional

A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy

NCT03473639
View directory record Official record
Conditions
Metastatic Breast Cancer, Breast Cancer
Interventions
Entinostat, Capecitabine
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Rochester, New York • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Sep 21, 2026, 2:33 PM EDT
Active, not recruiting Phase 2 Interventional

Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma

NCT03241186
View directory record Official record
Conditions
Mucosal Melanoma
Interventions
Ipilimumab, Nivolumab
Drug
Lead sponsor
Robert R. McWilliams, MD
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Jacksonville, Florida • Iowa City, Iowa • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Sep 21, 2026, 2:33 PM EDT
Completed Phase 2 Interventional

Phase II BGG492 Capsule Extension for Partial Epilepsy

NCT01338805
View directory record Official record
Conditions
Partial Onset Seizures
Interventions
BGG492
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 66 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Tallahassee, Florida • Hamilton, New Jersey • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 21, 2026, 2:33 PM EDT
Completed Not applicable Interventional Results available

Contingency Management for Smoking in Substance Abusers

NCT00807742
View directory record Official record
Conditions
Substance Abuse
Interventions
Nicotine Replacement Treatment (NRT), Brief Advice, Contingency Management, Non-Contingent Reinforcement
Drug · Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 21, 2026, 2:33 PM EDT
Completed Phase 2Phase 3 Interventional

Supraphysiological Doses of Levothyroxine as Adjunctive Therapy in Bipolar Depression

NCT01528839
View directory record Official record
Conditions
Bipolar Disorder
Interventions
L-Thyroxine, Placebo
Drug
Lead sponsor
Charite University, Berlin, Germany
Other
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Sep 21, 2026, 2:33 PM EDT
Withdrawn Phase 2 Interventional

A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone

NCT04965272
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Cariprazine 0.75 mg/day, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day, Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
36
States / cities
Little Rock, Arkansas • Colton, California • Costa Mesa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Sep 21, 2026, 2:33 PM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off

NCT01283594
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Tozadenant (SYN115) 60 mg BID, Placebo, Levodopa (L-dopa), Tozadenant (SYN115) 120 mg BID, Tozadenant (SYN115) 180 mg BID, Tozadenant (SYN115) 240 mg BID
Drug
Lead sponsor
Biotie Therapies Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
40
States / cities
Birmingham, Alabama • La Jolla, California • Loma Linda, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Sep 21, 2026, 2:33 PM EDT
Completed Not applicable Interventional

PRISM Neurofeedback Training for MDD Anhedonic Patients

NCT05869708
View directory record Official record
Conditions
Depression, Anhedonia
Interventions
Active RS-EFP, Sham RS-EFP
Device
Lead sponsor
GrayMatters Health Ltd.
Industry
Eligibility
22 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 21, 2026, 2:33 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)

NCT00626990
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide, DNA methylation analysis, laboratory biomarker analysis, adjuvant therapy, quality-of-life assessment, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years to 120 Years
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2029
U.S. locations
72
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 57 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2023 · Synced Sep 21, 2026, 2:33 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy

NCT00908349
View directory record Official record
Conditions
Partial Epilepsy
Interventions
Oxcarbazepine XR
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 66 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
20
States / cities
Huntsville, Alabama • Northport, Alabama • Phoenix, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 21, 2026, 2:33 PM EDT
Terminated Phase 2 Interventional Results available

Everolimus Versus Placebo in Head and Neck Cancer

NCT01111058
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Everolimus (RAD 001), Placebo
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
17
States / cities
Miami, Florida • Chicago, Illinois • Harvey, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Sep 21, 2026, 2:33 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)

NCT01587144
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Lucanthone, Temozolomide (TMZ), Radiation, Placebo
Drug · Radiation
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
La Jolla, California • Orange, California • Amherst, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Sep 21, 2026, 2:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

PRF + Minocycline vs Arestin in Non-surgical Perio Therapy

NCT07437209
View directory record Official record
Conditions
Non-surgical Periodontal Therapy
Interventions
Arestin, PRF + M
Drug · Biological
Lead sponsor
Center for Advanced Rejuvenation and Esthetics
Network
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 21, 2026, 2:33 PM EDT
Recruiting Phase 3 Interventional

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

NCT06876714
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2+ Breast Cancer
Interventions
Trastuzumab (Herceptin), Pertuzumab, Echocardiography, Multigated Acquisition Scan, Mammography, Ultrasound, Magnetic Resonance Imaging, Biospecimen Collection, Questionnaire Administration
Biological · Procedure · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
686
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Jonesboro, Arkansas + 528 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 21, 2026, 2:33 PM EDT
Terminated Phase 3 Interventional Results available

D-PLEX 302: Efficacy and Safety of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery

NCT03558984
View directory record Official record
Conditions
Surgical Site Infection, Sternal Infection, Cardiac Surgery
Interventions
D-PLEX, Standard of Care
Drug · Other
Lead sponsor
PolyPid Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Rochester, Minnesota • Huston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 21, 2026, 2:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Altitudes for Caregivers

NCT06094647
View directory record Official record
Conditions
Care Burden, Care Giving Burden, Caregiver Burnout, Caregiver Stress, Caregiver Wellbeing, Support, Family
Interventions
Altitudes USA
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Sep 21, 2026, 2:33 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration

NCT01122511
View directory record Official record
Conditions
Subfoveal Choroidal Neovascularization, Age-Related Maculopathy
Interventions
700 ug dexamethasone, ranibizumab, sham
Drug · Biological · Other
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Fort Myers, Florida • Abilene, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2012 · Synced Sep 21, 2026, 2:33 PM EDT
Completed Not applicable Interventional Results available

Jackson Pediatric Acupressure for Opioid Tapering

NCT05025384
View directory record Official record
Conditions
Iatrogenic Withdrawal Syndrome
Interventions
Acupressure
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
34 Weeks and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Sep 21, 2026, 2:33 PM EDT
Active, not recruiting Not applicable Interventional

Supervised Aerobic Training During or After Chemotherapy for Operable Breast Cancer

NCT01943695
View directory record Official record
Conditions
Breast Cancer
Interventions
Aerobic Training, Educational Information, Supervised Home Based Training
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 21, 2026, 2:33 PM EDT